FrancophonIA/ELRC3.0 huggingface dataset:
English: In paediatric patients, results from regression analyses of pharmacokinetic data suggest that co-administration of dexamethasone with caspofungin may result in clinically meaningful reductions in caspofungin trough concentrations.
Maltese: F'pazjenti pedjatriċi, ir-riżultati minn analiżijiet ta' rigressjoni ta' informazzjoni farmakokinetika jissuġġerixxu li l-għoti ta' dexamethasone ma' caspofungin jista' jirriżulta fi tnaqqis kliniku sinifikanti fl-inqas konċentrazzjonijiet ta' caspofungin.
English: In two clinical studies performed in healthy adult subjects, cyclosporin A (one 4 mg/kg dose or two 3 mg/kg doses 12 hours apart) increased the AUC of caspofungin by approximately 35 %.
Maltese: F'żewġ studji kliniċi li saru fuq individwi adulti b'saħħithom, cyclosporin A (doża waħda ta' 4 mg/kg jew żewġ dożi ta' 3 mg/kg 12-il siegħa 'l bogħod minn xulxin) żied l-AUC ta' caspofungin b'madwar 35%.
English: If you weigh more than 80 kg, you may need a different dose.
Maltese: Jekk inti tiżen aktar minn 80 kg, għandu mnejn tkun teħtieġ doża differenti.
English: Possibly histamine-mediated adverse reactions, including rash, facial swelling, angioedema, pruritus, sensation of warmth, or bronchospasm have been reported and may require discontinuation and/or administration of appropriate treatment.
Maltese: Reazzjonijiet avversi possibbilment medjati mill-istamina, inkluż raxx, nefħa fil-wiċċ, anġjoedima, ħakk, sensazzjoni ta' sħana, jew bronkospażmu kienu rrappurtati u jistgħu jkunu jeħtieġu twaqqif u/jew għoti ta' kura xierqa.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains: 70 mg caspofungin(as acetate).
Maltese: Kull kunjett fih: 70 mg caspofungin (bħala acetate).
English: Patients with rare hereditary problems of fructose intolerance or sucrase-isomaltase insufficiency should not take this medicinal product (see section 2).
Maltese: Pazjenti bi problemi ereditarji rari ta' intolleranza għallfructose jew insuffiċjenza ta' sucrase-isomaltase m'għandhomx jieħdu dan il-prodott mediċinali (ara sezzjoni 2).
English: Standardised techniques for susceptibility testing have been established for yeasts by EUCAST.
Maltese: Metodi standardizzati għall-ittestjar tas-suxxettibilità ġew stabbiliti għal ħmira minn EUCAST.
English: • Treatment of invasive candidiasis in adult or paediatric patients.
Maltese: • Trattament ta' kandidjasi invażiva f'pazjenti adulti jew pedjatriċi.
English: The incidence of resistance to caspofungin by various clinical isolates of Aspergillus is rare.
Maltese: L-inċidenza tar-reżistenza għal caspofungin mid-diversi iżolati kliniċi ta' Aspergillus hija rari.
English: Investigations blood potassium decreased, blood albumin decreased blood creatinine increased, red blood cells urine positive, protein total decreased, protein urine present, prothrombin time prolonged, prothrombin time shortened, blood sodium decreased, blood sodium increased, blood calcium decreased, blood calcium increased, blood chloride decreased, blood glucose increased, blood magnesium decreased, blood phosphorus decreased, blood phosphorus increased, blood urea increased, activated partial thromboplastin time prolonged, blood bicarbonate decreased, blood chloride increased, blood potassium increased, blood pressure increased, blood uric acid decreased, blood urine present, breath sounds abnormal, carbon dioxide decreased, immunosuppressant drug level increased, international normalised ratio increased, urinary casts, white blood cells urine positive, and pH urine increased.
Maltese: Investigazzjonijiet tnaqqis talpotassju fiddemm, tnaqqis tal-albumina fiddemm żieda tal-kreatinina fid-demm, preżenza ta' ċelloli ħomor tad-demm fl-awrina, tnaqqis fit-total ta' proteini, preżenza tal-proteini flawrina, żieda fil-ħin ta' prothrombin, tnaqqis fil-ħin ta' prothrombin, tnaqqis tas-sodju fid-demm, żieda tas-sodju fid-demm, tnaqqis talkalċju fid-demm, żieda tal-kalċju fid-demm, tnaqqis tal-chloride fiddemm, żieda tal-glukożju fid-demm, tnaqqis tal-manjeżju fid-demm, tnaqqis tal-fosfru fid-demm, żieda tal-fosfru fid-demm, żieda tal-urea fid-demm, ħin ta' thromboplastin parzjali attivat imtawwal, tnaqqis talbikarbunat tad-demm, żieda talchloride fid-demm, żieda talpotassju fid-demm, żieda filpressjoni tad-demm, tnaqqis tal-uric acid fid-demm, demm fl-awrina preżenti, ħsejjes mhux normali mannifs, tnaqqis fil-carbon dioxide, żieda fil-livell ta' mediċina immunosuppressanti, żieda filproporzjon normalizzat internazzjonali, casts tal-awrina, żieda fiċ-ċelloli bojod tad-demm, u żieda fil-pH tal-awrina.
English: Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.
Maltese: Caspofungin mhuwiex substrat għall-P-glikoproteina u huwa substrat fqir għall-enzimi taċ-ċitokromu P450.
English: Pharmacokinetic data from one 10-month old child receiving the 50 mg/m2 daily dose indicated an AUC0-24 hr within the same range as that observed in older children and adults at the 50 mg/m2 and the 50 mg dose, respectively, while in one 6-month old child receiving the 50 mg/m2
Maltese: Tagħrif farmakokinetiku minn tarbija waħda ta' 10 xhur li rċeviet id-doża ta' 50 mg/m2 kuljum indika AUC0-24hr fl-istess medda bħal dik osservata fi tfal akbar u l-adulti bid-doża ta' 50 mg/m2 u d-doża ta' 50 mg, rispettivament, filwaqt li f'tarbija waħda ta' 6 xhur li rċeviet id-doża ta' 50 mg/m2, l-AUC0-24hr kienet kemxejn ogħla.
English: Caspofungin Accord may also cause Serious Cutaneous Adverse Reactions such as Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).
Maltese: Serji ta' Taħt il-Ġilda bħas-Sindrome ta' Stevens-Johnson (SJS) u nekrolożi epidermali tossika (TEN).
English: This belongs to a group of medicines called anti-fungals.
Maltese: Din tagħmel parti minn grupp ta' mediċini msejħa antifungali.
English: Race: Patient pharmacokinetic data indicated that no clinically significant differences in the pharmacokinetics of caspofungin were seen among Caucasians, Blacks, Hispanics, and Mestizos.
Maltese: Tagħrif farmakokinetiku mill-pazjenti indika li ma dehrux differenzi kliniċi sinifikanti filfarmakokinetiċi ta' caspofungin fost il-Kawkasi, is-Suwed, l-Ispaniċi, u l-Mestizos.
English: Renal impairment
Maltese: Mhux Rakkomandat
English: There is no clinical experience in adult patients with severe hepatic impairment (Child-Pugh score greater than 9) and in paediatric patients with any degree of hepatic impairment (see section 4.4).
Maltese: M'hemmx esperjenza klinika f'pazjenti adulti b'indeboliment epatiku sever (punteġġ Child-Pugh akbar minn 9) u f'pazjenti pedjatriċi bi kwalunkwe livell ta' indeboliment tal-fwied (ara sezzjoni 4.4).
English: An independent expert panel determined that 41 % (26/63) of patients receiving at least one dose of caspofungin had a favourable response.
Maltese: Panel ta' esperti indipendenti stabbilixxa li 41% (26/63) tal-pazjenti li rċevew mill-anqas doża waħda ta' caspofungin kellhom rispons favorevoli.
English: There were transient increases in liver ALT and AST of less than or equal to 3-fold the upper limit of normal (ULN) when caspofungin and cyclosporin were co-administered, that resolved with discontinuation of the medicinal products.
Maltese: Kien hemm żidiet għaddiena fl-ALT u l-AST fil-fwied ta' inqas minn jew ugwali għal tliet darbiet il-limitu ta' fuq tan-normal (ULN) meta caspofungin u cyclosporin ingħataw flimkien, li marru bit-twaqqif tal-prodotti mediċinali.
English: Method of administration
Maltese: Mekkaniżmu ta' reżistenza
English: • Chills
Maltese: GĦAMLA
English: However, in adult patients with invasive candidiasis, oesophageal candidiasis, or invasive aspergillosis who received multiple daily doses of caspofungin 50 mg, there was no significant effect of mild to advanced renal impairment on caspofungin concentrations.
Maltese: Madankollu, f'pazjenti adulti b'kandidjasi invażiva, kandidjasi esofagali, jew asperġillożi invażiva li rċevew dożi multipli kuljum ta' caspofungin 50 mg, ma kienx hemm effett sinifikanti ta' indeboliment renali ħafif sa avanzat fuq il-konċentrazzjonijiet ta' caspofungin.
English: The study excluded patients with suspected Candida endocarditis, meningitis, or osteomyelitis.
Maltese: L-istudju eskluda pazjenti ssuspettati li kellhom endokardite, meninġite, jew osteomijelite kkawżata minn Candida.
English: The safety information on treatment durations longer than 4 weeks is limited.
Maltese: L-informazzjoni dwar is-sigurtà ta' tul ta' kura ta' iżjed minn 4 ġimgħat hija limitata.
English: In neonates and infants (<3 months) receiving caspofungin at 25 mg/m2 daily (corresponding mean daily dose of 2.1 mg/kg), caspofungin peak concentration (C1 hr) and caspofungin trough concentration (C24 hr) after multiple doses were comparable to that seen in adults receiving caspofungin at 50 mg daily.
Maltese: (doża medja korrispondenti ta' 2.1 mg/kg kuljum), l-akbar konċentrazzjoni ta' caspofungin fil-plażma (C1 hr) u l-inqas konċentrazzjoni ta' caspofungin fil-plażma (C24 hr) wara dożi multipli kienu komparabbli ma' dawk li dehru f'persuni adulti li rċevew caspofungin f'doża ta' 50 mg kuljum.
English: Day 1 [not to exceed 70 mg daily]) to liposomal amphotericin B (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on liposomal amphotericin B) as empirical therapy in paediatric patients with persistent fever and neutropenia.
Maltese: L-ewwel studju, li rreġistra 82 pazjent ta' bejn 2 u 17-il sena, kien studju double-blind, randomizzat li qabbel caspofungin (50 mg/m2 IV darba kuljum wara loading dose ta' 70-mg/m2 f'Jum 1 [li m'għandux jaqbeż 70 mg kuljum]) ma' amphotericin B liposomali (3 mg/kg IV kuljum) b'mod ta' trattament ta' 2:1 (56 fuq caspofungin, 26 fuq amphotericin B liposomali) bħala terapija empirika f'pazjenti pedjatriċi b'deni persistenti u newtropenija.
English: Renal and urinary disorders renal failure, renal failure acute
Maltese: Disturbi fil-kliewi u fis-sistema urinarja indeboliment tal-kliewi, indeboliment akut tal-kliewi
English: Data from 5 clinical studies completed in 171 paediatric patients suggest that the overall incidence of clinical adverse experiences (26.3%; 95% CI -19.9, 33.6) is not worse than reported for adults treated with caspofungin (43.1%; 95% CI -40.0, 46.2).
Maltese: 3%; 95% CI -19.9, 33.6) ma kinitx agħar minn dik irrappurtata għalladulti kkurati b'caspofungin (43.1%; 95% CI -40.0, 46.2).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains: 50 mg caspofungin (as acetate)
Maltese: Kull kunjett fih: 50 mg caspofungin (bħala acetate).
English: Caspofungin acetate inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of many filamentous fungi and yeast.
Maltese: L-aċetat ta' caspofungin jimpedixxi s-sinteżi ta' beta (1,3)-D-glucan, komponent essenzjali tal-ħajt taċ-ċelloli ta' ħafna fungi u ħmira li fihom fibri qishom ħjut.
English: Laboratory abnormalities in liver function tests have been seen in healthy volunteers and adult and paediatric patients treated with caspofungin.
Maltese: Dehru riżultati mhux normali f'testijiet tal-laboratorju tal-funzjoni tal-fwied f'voluntiera f'saħħithom u f'pazjenti adulti u pedjatriċi kkurati b'caspofungin.
English: When caspofungin is co-administered to paediatric patients (12 months to 17 years of age) with inducers of drug clearance, such as rifampicin, efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, a caspofungin dose of 70-mg/m2 daily (not to exceed an actual daily dose of 70 mg) should be considered.
Maltese: nevirapine, phenytoin, dexamethasone, jew carbamazepine, għandha tiġi kkunsidrata doża ta' caspofungin ta' 70-mg/m2 kuljum (li m'għandhiex taqbeż doża attwali ta' 70 mg kuljum).
English: A single 70 mg loading dose should be administered on Day-1, followed by 50 mg daily thereafter.
Maltese: Fl-ewwel jum għandha tingħata loading dose waħda ta' 70 mg, li mbagħad tkun segwita minn 50 mg kuljum.
English: The average exposure in an adult patient weighing 80 kg was predicted to be about 23 % lower than in an adult patient weighing 60 kg (see section 4.2).
Maltese: L-esponiment medju f'pazjent adult li jiżen 80 kg kien imbassar li huwa madwar 23% inqas milli f'pazjent adult li jiżen 60 kg (ara sezzjoni 4.2).
English: Reduced volume infusion (reconstituted Caspofungin Accord added to 100 mL) final concentration
Maltese: Infużjoni ta' volum imnaqqas (Caspofungin Accord rikostitwit miżjud ma' konċentrazzjoni finali ta' 100 mL)
English: 35 mg for moderate hepatic impairment (from one 50 mg vial) at reduced volume
Maltese: 35 mg għal indeboliment moderat tal-fwied (minn kunjett wieħed ta' 50 mg) f'volum imnaqqas
English: However, caspofungin has been shown to interact with other medicinal products in pharmacological and clinical studies (see below).
Maltese: Madankollu, caspofungin intwera li jinteraġixxi ma' prodotti mediċinali oħra fi studji farmakoloġiċi u kliniċi (ara taħt).
English: Gender: Caspofungin plasma concentrations were on average 17-38 % higher in women than in men.
Maltese: Bħala medja, il-konċentrazzjonijiet ta' caspofungin fin-nisa kienu 17-38% ogħla milli fl-irġiel.
English: The caspofungin plasma concentrations in these adolescents were reduced relative to adults receiving 70 mg daily, the dose most often administered to adolescents.
Maltese: Ilkonċentrazzjonijiet fil-plażma ta' caspofungin f'dawn l-adoloxxenti kienu mnaqqsa meta mqabbla ma' persuni adulti li rċevew 70 mg kuljum, id-doża li ngħatat l-aktar ta' spiss lill-adoloxxenti.
English: This medicinal product contains sucrose.
Maltese: Dan il-prodott mediċinali fih is-sucrose.
English: (maximum 70 mg daily), the caspofungin plasma AUC0-24 hr after multiple doses was comparable to that seen in adults receiving caspofungin at 50 mg daily and to that in older children (2 to 11 years of age) receiving the 50 mg/m2 daily dose.
Maltese: (massimu 70 mg kuljum), l-AUC0-24hr ta' caspofungin fil-plażma kienet ġeneralment komparabbli ma' dik li dehret f'persuni adulti li rċevew caspofungin f'doża ta' 50 mg kuljum.
English: In some adult and paediatric patients with serious underlying conditions who were receiving multiple concomitant medications with caspofungin, cases of clinically significant hepatic dysfunction, hepatitis and hepatic failure have been reported; a causal relationship to caspofungin has not been established.
Maltese: F'xi pazjenti adulti u pedjatriċi li kellhom kondizzjonijiet serji eżistenti li kienu qed jirċievu ħafna mediċini f'daqqa flimkien ma' caspofungin, kienu rrappurtati każijiet ta' funzjoni ħażina tal-fwied, epatite u insuffiċjenza epatika sinifikanti b'mod kliniku; ma ġiex stabbilit jekk caspofungin kienx il-kawża ta' dan.
English: Ask your doctor for more information.
Maltese: Sorsi oħra ta' informazzjoni
English: Caspofungin Accord 50 mg powder for concentrate for solution for infusion 10 mL Type I clear glass vial with bromobutyl rubber stopper and red aluminium seal with transparent plastic flip off button.
Maltese: Caspofungin Accord 50 mg trab għal konċentrat għal soluzzjoni għal infużjoni Kunjett tal-ħġieġ ċar ta' Tip I ta' 10 mL b'tapp tal-lastku tal-bromobutyl u siġill tal-aluminju aħmar b'buttuna tal-plastik trasparenti li tista' tinqala'.
English: In young children and toddlers (ages 12 to 23 months) receiving caspofungin at 50 mg/m2 daily
Maltese: Fl-adoloxxenti (etajiet minn 12 sa 17-il sena) li rċevew caspofungin f'doża ta' 50 mg/m2 kuljum
English: INSTRUCTIONS FOR USE IN PAEDIATRIC PATIENTS (Caspofungin Accord 70 mg)
Maltese: ADULTI (Caspofungin Accord 70 mg)
English: • Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile,
Maltese: • Terapija empirika għal infezzjonijiet fungali preżunti (bħal Candida jew Aspergillus) f'pazjenti newtropeniċi febbri adulti jew pedjatriċi.
English: Reduced volume infusions in 100 mL may be used, when medically necessary, for 50 mg or 35 mg daily doses.
Maltese: Meta jkun medikament meħtieġ, jistgħu jintużaw infużjonijiet ta' volum imnaqqas f'100 mL, għad-dożi ta' 50 mg jew 35 mg kuljum.
English: Hepatobiliary disorders elevated liver enzyme levels (AST, ALT)
Maltese: Disturbi fil-fwied u fil-marrara żieda fil-livelli tal-enzimi fil-fwied (AST, ALT)
English: neutropaenic adult or paediatric patients.
Maltese: Terapija Empirika f'Pazjenti Newtropeniċi Febbrili Adulti:
English: In a retrospective study of 40 patients treated during marketed use with caspofungin and cyclosporin for 1 to 290 days (median 17.5 days), no serious hepatic adverse reactions were noted (see section 4.4).
Maltese: Fi studju retrospettiv ta' 40 pazjent ittrattati waqt l-użu kummerċjalizzat b'caspofungin u cyclosporin għal 1 sa 290 ġurnata (medjan 17.5 ġranet), ma ġew innotati l-ebda reazzjonijiet avversi serji fil-fwied (ara sezzjoni 4.4).
English: Alternatively, the volume (mL)c of reconstituted Caspofungin Accord can be added to a reduced volume of 0.9 %,
Maltese: B'mod alternattiv, ilvolum (ml)c ta' Caspofungin Accord rikostitwit jista' jiġi miżjud ma' volum imnaqqas ta' 0.9
English: 0.45 %, or 0.225 % Sodium Chloride solution for infusion or Lactated Ringers solution for infusion, not to exceed a final concentration of 0.5 mg/mL.
Maltese: %, 0.45 %, jew 0.225 % soluzzjoni għal infużjoni ta' Klorur tas-Sodju jew soluzzjoni għal infużjoni Lactated ta' Ringers, li m'għandhiex taqbeż konċentrazzjoni finali ta' 0.5 mg/mL.
English: Caspofungin did not influence the pharmacokinetics of amphotericin B, itraconazole, rifampicin or mycophenolate mofetil.
Maltese: Dan jinkludi mediċini li ksibt mingħajr riċetta, inkluż mediċini magħmulin mill-ħxejjex.
English: In limited clinical experience, resistance to caspofungin in patients with invasive aspergillosis has been observed.
Maltese: F'esperjenza klinika limitata, kienet osservata reżistenza għal caspofungin f'pazjenti b'asperġillożi invażiva.
English: After two weeks' administration rifampicin had limited effect on AUC, but trough levels were 30 % lower than in adult subjects who received caspofungin alone.
Maltese: Wara ġimagħtejn għoti, rifampicin kellu effett limitat fuq l-AUC, iżda l-inqas livelli kienu 30% iżjed baxxi milli f'individwi adulti li rċevew caspofungin waħdu.
English: Development of in vitro resistance to caspofungin by Aspergillus species has been identified.
Maltese: Kien identifikat żvilupp ta' reżistenza in vitro għal caspofungin mill-ispeċijiet Aspergillus.
English: Patients in the non-comparative Aspergillus study often had serious predisposing medical conditions (e.g., bone marrow or peripheral stem cell transplants, haematologic malignancy, solid tumours or organ transplants) requiring multiple concomitant medications.
Maltese: Il-pazjenti fl-istudju mhux komparattiv dwar l-Aspergillus sikwit kellhom kundizzjonijiet mediċi serji ta' predispożizzjoni (eż. trapjanti tal-mudullun jew tal-istem cells periferali, tumuri ematoloġiċi, tumuri solidi jew trapjanti tal-organi) li kienu jeħtieġu diversi medikazzjonijiet konkomitanti.
English: However, paediatric patients probably have a different adverse event profile compared to adult patients.
Maltese: Madankollu, pazjenti pedjatriċi probabbilment għandhom profil ta' każijiet avversi differenti meta mqabbel ma' pażjenti adulti.
English: c Caspofungin Accord is formulated to provide the full labeled vial dose (50 mg) when 10 mL is withdrawn from the vial.
Maltese: ċ Caspofungin Accord huwa fformulat sabiex jipprovdi d-doża ttikkettjata kollha tal-kunjett (50 mg) meta jinġibdu 10 mL mill-kunjett.
English: Although the doses of prior antifungal therapies in 5 patients enrolled as refractory were lower than those often administered for invasive aspergillosis, the favourable response rate during therapy with caspofungin was similar in these patients to that seen in the remaining refractory patients (2/5 versus 17/48, respectively).
Maltese: Għalkemm id-dożi tat-terapiji antifungali preċedenti f'5 pazjenti rreġistrati bħala refrattorji kienu iżjed baxxi minn dawk li sikwit jingħataw għal asperġillożi invażiva, ir-rata ta' rispons favorevoli matul it-terapija b'caspofungin f'dawn il-pazjenti kienet simili għal dik li dehret filbqija tal-pazjenti refrattorji (2/5 kontra 17/48, rispettivament).
English: • rash, skin peeling, mucous membrane sores, hives, large areas of peeling skin.
Maltese: • raxx, tqaxxir tal-ġilda, selħiet fil-membrana mukuża, ħorriqija, partijiet kbar tal-ġilda jitqaxxru.
English: Aseptically transfer this volume (mL)c of reconstituted Caspofungin Accord to an IV bag (or bottle) containing 250 mL of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride solution for infusion or Lactated Ringers solution for infusion.
Maltese: Ittrasferixxi b'mod asettiku dan il-volum (ml)c ta' Caspofungin Accord rikostitwit għal borża (jew flixkun) IV li fiha 250 ml ta' 0.9%, 0.45 %, jew 0.225 % soluzzjoni għal infużjoni ta' Klorur tas-Sodju, jew soluzzjoni għal infużjoni Lactated ta' Ringers.
English: An additional gamma-phase also occurs with a half-life of 45 hours.
Maltese: Isseħħ ukoll fażi gamma addizzjonali b'half-life ta' 45 siegħa.
English: Eligible patients had received chemotherapy for malignancy or had undergone hematopoietic stem-cell transplantation, and presented with neutropaenia (<500 cells/mm3 for 96 hours) and fever (>38.0°C)
Maltese: Il-pazjenti eliġibbli kienu rċevew kemjoterapija għal tumuri jew kienu sottoposti għal trapjant ematopoetiku tal-istem cells, u ppreżentaw newtropenija (<500 ċellola/mm3 għal 96 siegħa) u deni (>38.0°C) li ma rrispondewx għal
English: Clinical studies in healthy adult volunteers show that the pharmacokinetics of caspofungin are not altered to a clinically relevant extent by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.
Maltese: Studji kliniċi fuq voluntiera adulti b'saħħithom juru li l-farmakokinetiċi ta' caspofungin ma jinbidlux b'mod klinikament sinifikanti b'itraconazole, amphotericin B, mycophenolate, nelfinavir, jew tacrolimus. Caspofungin ma influwenzax il-farmakokinetiċi ta' amphotericin B, itraconazole, rifampicin jew mycophenolate mofetil.
English: Each pack contains one vial of powder.
Maltese: Kull pakkett fih kunjett ta' trab wieħed.
English: In a second study, patients with invasive candidiasis received daily doses of caspofungin at 50 mg/day (following a 70-mg loading dose on Day 1) or caspofungin at 150 mg/day (see section 4.8).
Maltese: Fit-tieni studju, pazjenti b'kandidjasi invażiva rċevew dożi ta' kuljum ta' caspofungin b'50 mg/kuljum (wara doża inizjali qawwija ta' 70 mg f'Jum 1) jew caspofungin b'150 mg/kuljum (ara sezzjoni 4.8).
English: The study compared caspofungin at 50 mg daily (following a 70-mg loading dose on Day 1) versus 150 mg daily in the treatment of invasive candidiasis.
Maltese: L-istudju qabbel caspofungin b'50 mg kuljum (wara doża inizjali qawwija ta' 70 mg f'Jum 1) ma' 150 mg kuljum fil-kura ta' kandidjasi invażiva.
English: 35 mg for moderate hepatic impairment (from one 50 mg vial)
Maltese: 35 mg għal indeboliment moderat tal-fwied (minn kunjett wieħed ta' 50 mg)
English: Caspofungin Accord 50 mg powder for concentrate for solution for infusion Caspofungin Accord 70 mg powder for concentrate for solution for infusion caspofungin
Maltese: Caspofungin Accord 50 mg trab għal konċentrat għal soluzzjoni għal infużjoni Caspofungin Accord 70 mg trab għal konċentrat għal soluzzjoni għal infużjoni
English: Step 2 Addition of reconstituted Caspofungin Accord to patient infusion solution Diluents for the final solution for infusion are: sodium chloride solution for injection 9 mg/mL or lactated Ringer's solution.
Maltese: Pass 2 Żieda ta' Caspofungin Accord rikostiwit mas-soluzzjoni għall-infużjoni tal-pazjent Id-dilwenti tas-soluzzjoni finali għal infużjoni huma: soluzzjoni ta' klorur tas-sodju għal injezzjoni ta' 9 mg/mL jew soluzzjoni lactated ta' Ringer.
English: Alternatively, the volume (mL)c of reconstituted Caspofungin Accord can be added to a reduced volume of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride solution for infusion or Lactated Ringers solution for infusion, not to exceed a final concentration of 0.5 mg/mL.
Maltese: B'mod alternattiv, il-volum (ml)c ta' Caspofungin Accord rikostitwit jista' jiġi miżjud ma' volum imnaqqas ta' 0.9 %, 0.45 %, jew 0.225 % soluzzjoni għal infużjoni ta' Klorur tas-Sodju jew soluzzjoni għal infużjoni Lactated ta' Ringers, li m'għandhiex taqbeż konċentrazzjoni finali ta' 0.5 mg/ml.